In immediate-release tablet manufacture, hypromellose with a nominal viscosity of 5 cP (methoxy content 28–30%, hydroxypropoxy content 7–12%, substitution type 2910) is applied as a wet-granulation binder at a dry use level of 2–5% w/w relative to core weight. The binder solution is prepared at 5–10% w/w by dispersing the powder in purified water heated to 80–90°C under a vacuum-equipped homogenizer, followed by cooling to 5–15°C to allow complete hydration; incomplete cooling produces undissolved gel particles that transfer to oversized granules after milling. Granulation is performed in a top-drive high-shear mixer with a 25 L bowl, impeller speed 350–500 rpm, and chopper speed 1500–3000 rpm. The binder solution is sprayed or poured at a volume of 25–35% w/w while power consumption is monitored by an endpoint algorithm; the maximum cohesive state is identified by a characteristic plateau in impeller power draw followed by a sharp decrease upon over-wetting. The wet mass is discharged through a 4–6 mm sieve and dried in a fluid-bed dryer with inlet air at 60–70°C and product temperature 40–45°C until loss on drying reaches 1.5–2.5%. Dried granules are milled through a cone mill fitted with a 0.8–1.0 mm screen at 1500 rpm. Tableting on a rotary press with pre-compression using 10–20 kN main compression force for 9 mm biconvex tooling produces tablet hardness 60–120 N; friability under USP <1216> remains below 1.0%, and disintegration under USP <701> is achieved within 15 min for soluble APIs. The HPMC binder forms a pH-independent hydrophilic bridge that yields lower friability than povidone in high-speed compression. Compliance is anchored to the USP/NF Hypromellose monograph, Ph. Eur. 0348, and JP; residual solvents are assessed by USP <467> and ICH Q3C; elemental impurities by ICH Q3D and USP <232>/<233>; microbiological quality by USP <61>/<62>. Terminal finished products include acetaminophen 500 mg immediate-release tablets, levofloxacin 500 mg film-coated tablets, and effervescent granule sachets. In effervescent granules, HPMC 5 cP functions as a binder for granulation before admixture of sodium bicarbonate and citric acid; residual moisture must be below 0.5% to prevent premature acid-base reaction.

What Limits Drug Release Retardation When HPMC 50 cP Replaces K4M in Hydrophilic Matrices?

Direct substitution of low-viscosity 50 cP hypromellose for 4000 mPa·s hypromellose K4M in hydrophilic matrix tablets is constrained by gel-layer erosion rate and polymer disentanglement. At a dry matrix loading of 20–40% w/w, the 50 cP grade can be dry-blended with microcrystalline cellulose, spray-dried lactose, and 0.5–1.0% w/w magnesium stearate in a bin blender at 15–20 rpm for 15–30 min; the blend is compressed on a rotary tablet press with 8–18 kN main compression force, 80–150 N hardness, and friability below 1.0%. Dissolution testing under USP <711> Apparatus 2 at 50 rpm in 900 mL media demonstrates that a 50 cP grade alone does not generate a polymer gel layer of sufficient mechanical integrity for 24 h extended release; for highly soluble APIs with dose-to-solubility ratios above 250 mL, the low-viscosity matrix releases more than 70% of the dose within 6–8 h. Consequently, the 50 cP grade is used as a co-matrix former with HPMC K4M or K15M at ratios from 1:1 to 1:3 to modulate the initial release phase without compromising compressibility. The 15 cP grade offers higher gel strength and is preferred for low-dose, low-solubility APIs where release retardation over 8–12 h is acceptable. Process limits include avoiding wet granulation with excessive water because low-viscosity HPMC hydrates rapidly and can generate a sticky wet mass above 30% w/w binder solution. Matrix integrity is assessed by photographic gel-layer thickness measurement and by USP <905> content uniformity; release specification limits follow FDA SUPAC-MR guidance for modified release. Batch-to-batch variability in the 50 cP grade viscosity within the monograph range of 40–60 cP can shift the t_80% dissolution time by approximately ±15%; therefore, incoming lot viscosity should be controlled with a USP <911> capillary viscometer or a rotational viscometer at 20°C. Terminal products include metformin hydrochloride 500 mg extended-release tablets formulated with HPMC K4M plus 50 cP grade as a burst-release modifier, and alfuzosin hydrochloride 10 mg matrix tablets using the 15 cP grade in a compression coating design.

Film-Coating Spray Parameters Are Governed by Solution Viscosity Below 500 mPa·s

Aqueous film coating with HPMC 5 cP uses a 6–12% w/w polymer solution; HPMC 15 cP requires a lower concentration of 4–8% w/w to maintain sprayable viscosity below 500 mPa·s at 25°C. The solution is prepared by dispersing HPMC powder in hot purified water at 80–90°C under axial flow agitation, followed by cooling to 5–10°C and addition of plasticizer. Polyethylene glycol 400 or propylene glycol is added at 10–25% w/w of dry polymer to prevent film brittleness; talc or micronized titanium dioxide is added at 20–30% w/w of dry polymer as an anti-tack agent. Coating is performed in a side-vented perforated pan, such as a 24-inch O'Hara LabCoat II or Glatt GC Smart, with inlet air temperature 65–75°C, outlet air temperature 38–45°C, and bed temperature 40–43°C. Atomizing pressure of 1.0–1.5 bar produces droplets with Sauter mean diameter 10–30 μm; spray rate is maintained at 10–20 g/min for the 24-inch pan, and pan speed is set to 6–12 rpm. A coating weight gain of 2–4% w/w is sufficient for moisture-barrier and taste-masking purposes; higher weight gains above 6% w/w slow disintegration under USP <701> and are not recommended for immediate-release tablets. HPMC film is pH-independent and does not provide enteric protection; if enteric performance is required, hydroxypropyl methylcellulose phthalate or a methacrylic acid copolymer must be substituted. Curing is not required because HPMC films do not undergo thermal cross-linking, but tablets should be discharged at tablet bed moisture below 2.0%. Compliance is anchored to the USP/NF Hypromellose monograph, ICH Q3C residual solvents, and USP <467>; film-coated tablets are tested for friability under USP <1216>, disintegration under USP <701>, and dissolution under USP <711>. Terminal products include ibuprofen 200 mg film-coated tablets, vitamin C 500 mg coated tablets with moisture barrier, and paracetamol 650 mg caplet-shaped coated tablets. The 50 cP grade is excluded from film-coating operations because the concentration required to achieve acceptable barrier function produces solution viscosity exceeding 1500 mPa·s, which destabilizes spray atomization and leads to film roughness.

In hard capsule shell dipping, the rheological boundary is set by the thermal gelation of HPMC 5 cP at concentrations of 18–26% w/w in purified water. The solution is prepared under vacuum in a heated vessel at 85°C, then cooled to 20°C to give a viscosity of 800–2000 mPa·s. Stainless steel pin bars are preheated to 55–70°C and dipped into the cold solution for 5–15 seconds; thermal gelation on the pin surface forms a film of 0.10–0.15 mm thickness. Pin withdrawal speed is controlled at 10–30 mm/s to prevent ridge formation and wall-thickness variation. The gel-coated pins are rotated and dried in a multi-zone dryer at 25–35°C and 30–40% RH; final shell moisture is 3–6%. Below 2% moisture, shell brittleness increases and the incidence of cap splitting on automatic capsule-filling machines exceeds acceptable limits. HPMC capsule shells disintegrate in water within 30 min under USP <701> and do not cross-link with aldehyde-containing fill materials, which is a known failure mode for gelatin shells exposed to reactive aldehydes. Weight variation is controlled by USP <905>; dissolution of encapsulated dosage forms is tested under USP <711>. The 5 cP grade is preferred because the 15 cP grade at equivalent concentration raises solution viscosity above 3000 mPa·s and reduces pin drainage, creating thicker sidewalls and non-uniform cap formation. Terminal products include empty HPMC capsules for hygroscopic powder fill, delayed-release pellets, and high-potency low-dose APIs. In capsule-filling operations on a dosing-disk or tamping-pin machine, shell moisture below 4% is recommended to avoid static adhesion; above 6% shell deformation may occur during closing.

Oral Liquid Suspension Viscosity and Yield Stress

Oral liquid suspensions formulated with HPMC 5 cP or 15 cP use polymer concentrations of 0.5–2.0% w/w to raise low-shear viscosity and retard sedimentation of insoluble API particles. Hydration is initiated by dispersing the powder in hot purified water at 80–90°C; the dispersion is then cooled to 5–15°C and mixed for 4–8 h in a stainless steel jacketed vessel with a low-shear axial impeller at 100–300 rpm. The resulting solution exhibits pseudoplastic flow; at 20°C, the apparent viscosity measured with a Brookfield rotational viscometer at 20 rpm ranges from 50–500 mPa·s depending on grade and concentration. Suspensions based on HPMC remain stable over a pH range of 3.0–10.0; however, high concentrations of bivalent cations or inorganic salts reduce the cloud point and may induce aggregation at elevated temperature. In a reconstitutable dry suspension, HPMC 5 cP is incorporated as a dry blend with granulated excipients at 0.5–1.5% w/w; upon reconstitution with 60 mL water, the polymer hydrates within 30 min under manual shaking, generating a uniform suspension. Sedimentation volume is measured in a 100 mL graduated cylinder over 24 h; formulations with HPMC 15 cP at 1.0% w/w typically maintain sedimentation volume above 0.90, whereas the 5 cP grade at the same concentration produces lower yield stress and may require the addition of microcrystalline cellulose/carboxymethylcellulose sodium as a co-suspending agent. Compliance is assessed by USP <905> for dosage uniformity, USP <61>/<62> for microbial limits, and ICH Q3C for residual solvents; release of suspended API is confirmed under USP <711>. Terminal products include pediatric amoxicillin suspension, antacid suspension, and oral contrast media suspensions. The 50 cP grade is not typically selected for oral liquids because the concentration required for equivalent suspending properties increases the formulation viscosity beyond acceptable palatability and pourability limits.

When HPMC 5 cP Is Sterilized by Autoclave for Ophthalmic Vehicle Use

Hypromellose 5 cP is employed as an ophthalmic vehicle and irrigation solution component at 0.2–0.5% w/w in sterile balanced salt solution (BSS). The solution is prepared by cold hydration at 5–15°C for 4 h, then terminal sterilization is attempted by autoclaving at 121°C for 15 min. Terminal sterilization reduces apparent viscosity by 30–40% because polymer chain scission occurs under hydrolytic stress; therefore, when terminal sterilization is unavoidable, the pre-sterilization polymer concentration is increased by 40% to compensate. Aseptic filtration through a 0.22 μm polyethersulfone membrane is feasible only at concentrations up to 0.5% w/w; at higher concentrations, the solution exceeds the pressure limit of the filter capsule and requires 0.45 μm pre-filtration followed by aseptic processing. Sterility is tested by USP <71> membrane filtration; bacterial endotoxins are limited to <0.5 EU/mL by USP <85>; particulate matter is controlled by USP <789>. Biocompatibility for ocular contact is assessed under ISO 10993-1; the finished ophthalmic solution must be isotonic with tear fluid at 280–320 mOsmol/kg. The 50 cP grade is not appropriate as a capsular tamponade agent in cataract surgery because its zero-shear viscosity at 2% w/w is several orders of magnitude below the 50,000–100,000 mPa·s required for an ophthalmic viscosurgical device; that application demands HPMC with nominal viscosity in the 4000–5000 cP range or a high-molecular-weight hyaluronic acid derivative. Terminal products include ophthalmic irrigation solution, dry-eye drops, and gonioscopy contact fluid. In multi-dose ophthalmic containers, a preservative such as benzalkonium chloride is used; however, HPMC is compatible with non-ionic preservatives and incompatible with high concentrations of cationic preservatives at pH above 8.0 due to reduced solubility.